STAT3 and cancer: Silencing of SOCS3 causes decreased inactivation of STAT3, which also contributes to its constitutive activation and, thus, the progression of cancers such as hepatocellular carcinoma and cholangiocarcinoma in both cell and animal models [26,27,28].